Quarterly ResultAug 13, 2026, 06:17 AM
Rockwell Medical Q2 Net Sales Up 11% to $17.8M; Net Loss Improves
AI Summary
Rockwell Medical announced its second quarter 2026 financial results, reporting an 11% year-over-year increase in net sales to $17.8 million and a 30% rise in gross profit to $3.2 million. The company's net loss improved to $1.2 million, and it generated $2.1 million in cash flow from operations, boosting its cash position to $24.8 million. Rockwell Medical also reiterated its full-year 2026 guidance and highlighted new and renewed product purchase agreements, alongside regaining Nasdaq compliance after a reverse stock split.
Key Highlights
- Net Sales for Q2 2026 increased 11% year-over-year to $17.8 million.
- Gross Profit for Q2 2026 rose 30% year-over-year to $3.2 million, with gross margin expanding to 18%.
- Net Loss for Q2 2026 improved to $1.2 million from $1.5 million in Q2 2025.
- Generated $2.1 million in Cash Flow from Operations in Q2 2026, increasing cash to $24.8 million.
- Reiterated full-year 2026 guidance: Net Sales $70.0M-$75.0M, Gross Margin 18%-22%, Adjusted EBITDA $1.0M-$2.0M, and positive Operating Cash Flow.
- Entered a three-year product purchase agreement with Heritage Dialysis in May 2026.
- Renewed and extended product purchase agreement with aQua Dialysis for two years in May 2026.
- Completed a 1-for-10 reverse stock split effective July 1, 2026, and regained Nasdaq compliance.
Price Impact
More from RMTI